Invited Speakers

List of Invited Speakers (Tentative)

Arrange in order of the program booklets.
  • Farzin Farzaneh, Ph.D.

    • Affiliation
    • ▪ Chair of Molecular Medicine, King’s College London
    • E-mail : farzin.farzaneh@kcl.ac.uk
    • Biography
    • Supported by fellowships from Medical Research Council, Beit Memorial Trust and European Molecular Biology Organisation, studied at Universities of Aberdeen, Sussex and Amsterdam. Appointed to the faculty at King’s College London in 1985 and was awarded the Chair in Molecular Medicine in 1996. Published over 250 research articles with an average citation of over 30, and an Impact Factor of 47. Established and run a licensed GMP facility at King’s College London since 2001, for the development and production of cell and gene therapy based investigational medicinal products. This facility has produced the largest number of viral vectors for clinical trials in Europe. Appointed by the Commission on Human Medicines, as a member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group since 2016. Recipient of 2016 Distinguished Scientist Award of the US Society for Experimental Biology & Medicine. Elected to the “Fujian Province 100 Talent Programme” of the Chinese Academy of Medical Sciences, at the University of Huaqiao, in Xiamen, China, 2017. Appointed, Adjunct Professor and Consultant at Academy of Medical Sciences, Zheng Zhou University, China, 2017.
  • Hironori Nakagami, M.D., Ph.D.

    • Affiliation
    • ▪ Professor, Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Osaka
    • E-mail : nakagami@gts.med.osaka-u.ac.jp
    • Biography
    • Dr. Hironori Nakagami graduated from Nara Medical University (MD. 1994) and got PhD in Department of Geriatric Medicine, Osaka University Gradute School of Medicine (Prof. Toshio Ogihara and Ryuichi Morishita). He spent two years (2001-2003) as a research fellow in Brigham & Women’s Hospital, Harvard Medical School, Vascular Medicine (Prof. James K. Liao). After going back to Osaka University, he was an Assistant Professor for seven years (2003-2010) in Division of Gene Therapy Science (Prof. Yasufumi Kaneda). He is now Professor of Department of Health Development and Medicine, Osaka University Graduate School of Medicine since 2010.
      His research interests include cardiovascular diseases, metabolic syndrome, high blood pressure, and inflammatory diseases combination with novel immunotherapy, therapeutic vaccines. He is now editorial board member of several journals, such as Scientific Report, Geriatric and Gerontology International and Vaccones. He has been recently awarded the Osaka University Presidential Awards for Achievement in 2016 and 2017, and also High impact paper in Hypertension journal in 2018.
      Dr. Nakagami has focused on the translational research of therapeutic vaccines in collaboration with venture company. He is a pioneer of this novel field and now collaborated with a lot of research project teams for several diseases. We have already reported the Angiotensin II vaccine (Hypertension 2015, Stroke 2017), DPP-4 vaccine for Diabetes (PNAS 2014), PCSK9 vaccine for Dyslipidemia (PLoS One 2018) and S100A9 vaccines for anti-platelet drugs in each animal model. In terms of Angiotensin II vaccine project, the phase I clinical trial has been designed and first-in-patient was enrolled in 2018.
  • Zhe Zhang, Ph.D candidate

    • Affiliation
    • ▪ Ph.D candidate, National Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450052, China
    • E-mail : 2008henanzhangzhe@163.com
    • Biography
    • Zhe Zhang obtained her undergraduate degree in clinical medicine from Zhengzhou University from September 2008 to June 2013. She has been studying for doctoral degree at Zhengzhou University since September 2013. Her research interests include tumor vaccines and oncolytic viruses. From January 2013 to June 2014, she participated in the project of National Natural Science Foundation of China, “Molecular Mechanism of Adipocyte α7 nAChR Regulating the inflammatory effects of Acylated Protein in Obesity” (2014. 01-2016. 12, Project Label: 81300685), published paper: Wu J, Jiao ZY, Zhang Z, Tang ZH, Zhang HH, Lu HL, et al. Cross-talk between alpha7 nachr-mediated cholinergic pathway and acylation stimulating protein signaling in 3t3-l1 adipocytes: Role of nfkappab and stat3. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2015;93:335-342. (IF 2.250). From July 2014 to now, she has studied the issues of stem cells, tumor vaccines and oncolytic viruses at the National Center for International Research in Cell and Gene Therapy at Zhengzhou University. She has mastered the general skills of cell, molecular and animal experiments and cultivated certain scientific thinking. She has some experience in technologies such as iPSCs and CRISPR/Cas9. A second author's article has been accepted by Clinical Cancer Research, and another first author's article is being submitted.
  • Hiroyuki Nakamura, Ph.D.

    • Affiliation
    • ▪ Professor, Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan
    • E-mail : hiro@res.titech.ac.jp
    • Biography
    • Hiroyuki Nakamura was received his PhD from Tohoku University under the supervision of Professor Yoshinori Yamamoto in 1996. He became an assistant professor at Kyushu University (1995 – 1997) and at Tohoku University (1997 – 2002). He worked as a visiting assistant professor at University of Pittsburgh with Professor D. Curran (2000-2001). In 2002, he was appointed as an associate professor at Gakushuin University and promoted as a professor in 2006. In 2013, he was appointed as a professor at Tokyo Institute of Technology. He received the Chemical Society of Japan Award for Young Chemists in 1999, the Incentive Award of the Japanese Society for Molecular Target Therapy of Cancer in 2007, and Asian CORE Program/Advanced Research Lectureship Award in 2018. He became president of the Japanese Society of Neutron Capture Therapy (2015 – 2019). He is also a committee member of various academic societies, such as a Board of Councilor (2004 – present) and a technical committee of chemistry (2018 – present) in the International Society of Neutron Capture Therapy, an international committee of the International Society of Boron Chemistry (2010 – present), an International Advisory Board of Russian Chemical Bulletin (2019 – present), a local committee of the Society of Synthetic Organic Chemistry, Japan (2013 – present), a local committee of the Pharmaceutical Society of Japan (2018 – present), a committee of the Japanese Society for Molecular Target Therapy of Cancer (2009 – present), and a committee of the Japanese Society of Chemical Biology (2010 – present). His research interests include synthetic methodology, medicinal chemistry, chemical biology, photodynamic therapy, and neutron capture therapy.
  • Jin-Ho Choy, Ph.D.

    • Affiliation
    • ▪ Chair Professor, Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, Korea
      ▪ Academician, The National Academy of Sciences, Korea
      ▪ Appointed Professor, Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan
    • E-mail : jhchoy@dankook.ac.kr; jhchoy@ewha.ac.kr
    • Biography
    • Prof. Jin-Ho Choy received his B.S. (1970) and M.S. degrees (1972) in Chemical Engineering from Yonsei University, his Ph.D. degree (1979) in Chemistry from University of München (Ludwig-Maximilians Universität München), Germany and his second Ph.D in Engineering from Tokyo Institute of Technology (Tokyo Tech.), Japan. He was a professor in the department of chemistry at Seoul National University (1981-2004), and a distinguished professor and director of the Center for Intelligent Nano-Bio Materials (CINBM) at Ewha Womans University (2004-2019), and is currently a chair professor at Dankook University (2019-present), and an appointed professor at Tokyo Institute of Technology (2019-present). He was also a visiting professor of Laboratoire de Chimie du Solide du CNRS, Universite de Bordeaux I, France (1985-1986), department of materials engineering, University of Illinois at Urbana Champaign, USA (2003), department of applied chemistry, Kumamoto University, Japan (2008), and various laboratories in the world. He received an Academic Award from the Korean Chemical Society (2000), a National Science Award in Chemistry from the Korean Government (2003), a Distinguished Service Knight Medal from the French Government (Palmes Academiques ; Chevalier dans l’Ordre des Palmes Academiques (2003), a 1st Class National Science Medal (2006), a Korean Best Scientist Award from the President of Korea (2007), the Best Korea Award from Herald Business (2007), an Award of Role Models in Science from the Korean Government, an Award of Fellow from the Royal Society of Chemistry , UK (2008), a Culture Award in Science from Seoul City (2010), an Academic Award from Ewha Womans University (2012), a Proud Yonsei Engineer Award from Yonsei University (2012), and an Academic Award (SungOk) from Korean Ceramic Society (2015), and also became an Academician elected from the World Academy of Ceramics (2017), and from the National Academy of Science in Korea (2018) as well. His research interests include inorganic solids and nanomaterials with various physicochemical properties, 2D heterostructured nanomaterials, such as inorganic-inorganic, organic-inorganic, and bio-inorganic hybrids with dual functions and various intercalation compounds, 2D drug delivery systems with imaging and theranostic functions, and he has published more than 630 papers and 33 patents registered.
  • Won Jong Kim, Ph.D.

    • Affiliation
    • ▪ Professor, Department of Chemistry, Pohang University of Science and Technology, Pohang, Korea
    • E-mail : wjkim@postech.ac.kr
    • Biography
    • Prof. Won Jong Kim received his BSc from Hanyang University in 1998, and M.S. and Ph. D. in Biomolecular Engineering in 2004 at Tokyo Institute of Technology. During his graduate studies with Profs T. Akaike and A. Maruyama, he developed a polymer-mediated DNA detection system. From 2004 to 2007, he was a postdoctoral fellow at the University of Utah under the supervision of Prof. Sung Wan Kim. Currently, he is a tenured full professor at the Department of Chemistry, POSTECH. He received KCS-Wiley Young Chemist Award (2011), Wiley-PSK Journal of Polymer Science Young Scientist Award (2012), KCS-Award for the Advancement of Science (2014), and PSK-Mid-career Researcher Academy Award (2015). He is an associate editor of newly launched journal “Nanotheranostics”, and editorial member of “Materials Today Chemistry”, and advisory board member of “Biomaterials Science”.
      He has published ~130 original research papers. His papers were cited >4,000 times. (H-index >40)
      His research background is mainly focused on synthesizing polymeric drug/gene carriers, developing new chemistries for the polymeric carriers, and exploring their potential towards efficient delivery. Since he started his own independent career at POSTECH in Aug 2007, he has expanded his research interest in the area of developing new polymeric drug and gene carriers that are more cell-specific and biodegradable, and designing novel hybrid materials with inorganic nanoparticles including superparamagnetic, phothothermal, and pH-sensitive carriers for stimuli-sensitive applications. Also, using the basic principle of DNA strand exchange reaction, he developed various strategies for one-base mismatch detection. To this end, he and his group members have focused their research efforts on the polymer nanochannel systems for continuous DNA detection and label-free DNA detection systems using the intrinsic fluorescence of silver nanocluster. He also further extended the research subjects on delivery to gas molecule delivery like nitric oxide (NO) controlled release systems and its application for modulation of cell proliferation and anti-bacterial activity.
  • Yaohe /wang MD, Ph.D.

    • Affiliation
    • ▪ Professor of Cancer Cell and Gene Therapy, Barts Cancer Insitute, Queen Mary University of London
      ▪ Director of National Centre for International Research Centre in Cell and Gene Therapy, Executive director & Chief Scientific Officer, Sino-British Research Centre for Molecular Oncology, Academy of Medical Sciences, Zhengzhou University, Zhengzhou China
    • E-mail : Yaohe.wang@qmul.ac.uk
    • Biography
    • Dr. Yaohe Wang is a Professor of Cancer Cell and Gene Therapy and the head of Cancer Viro-immunotherapy Laboratory at Barts Cancer Institute, Queen Mary University of London. He is also the director of National Centre for International Research in Cell and Gene Therapy, the executive director and Chief Scientific officer of Sino-British Research Centre for Molecular Oncology at Zhengzhou University, which was jointly established in 2006 between Zhengzhou University and Queen Mary University of London. The major research interest in his Lab are is investigating the interaction of oncolytic viruses, tumour cells and host immune responses to design novel cancer therapeutic agents and regimens. Combination of oncolytic viruses with cancer cell therapy is the focus of a major new programme. Prof Wang has successfully secured millions pounds to undertake his interested research with a substantial track record of publications in prestigious scientific journals such as “Nature Biotechnology”, “The Journal of Clinical Investigation (JCI)”, “Gut”, and Nature Communications”, etc. His lab has made several original contributions to the field of cancer virotherapy and has been granted six patents. He serves as Editorial Board Member for several pioneer-reviewed Journals such as Gene Therapy, Molecular Therapy-Oncolytics etc. and also as a referee for International Founding organizations and Journals. Professor Wang’s long-term research aim is to develop more effective cancer cell and gene therapies based on the genetically engineered oncolytic virus platform, for prevention, diagnosis and treatment of human cancer, and advance them into clinical testing.
  • Chae-Ok Yun, Ph.D.

    • Affiliation
    • ▪ Professor, Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea
      ▪ Chief Executive Officer and Chief Scientific Officer, GeneMedicine, LTD, Seoul, Korea
    • E-mail : chaeok@hanyang.ac.kr ; chaeok@gene-medicine.com
    • Biography
    • Chae-Ok Yun is serving as a Full Professor in the Department of Bioengineering at Hanyang University, Korea. She is also an Adjunct Professor of Pharmaceuticals and Pharmaceutical Chemistry at University of Utah in United States, an Affiliate Professor at Medical School, University of Washington in United States, and Guest Professor at Sichuan University in China. Her research interests include cancer gene therapy, immunotherapy, angiogenesis, combination of viral vectors and non-viral vectors, nanomedicine, and tumor biology. She has published 193 articles in leading academic journals such as Nature Medicine, JNCI, JCI, Cancer Research, Clinical Cancer Research, Molecular Therapy, Biomaterials, Human Gene Therapy, and JBC and has registered over 95 patents. In addition, oncolytic adenovirus (GM101) developed by Professor Yun was evaluated in phase I clinical trial for recurrent cancers, which yielded promising results. Recently, Dr. Yun has been focusing on translating her cutting-edge oncolytic adenovirus pipelines into clinic through establishment of her own company GeneMedicine and active collaboration with global partners. She is currently serving as a chief/deputy editor or editorial member in well-recognized international journals, such as Molecular Therapy, BMC Cancer, Cancer Gene Therapy, Oncolytic virotherapy, Advanced Drug Delivery Review, Regenerative Therapy, and Biomaterials. She was awarded the Excellence in Research Award from American Society of Gene Therapy in 2002 and Excellent Professor in Research Achievement from Yonsei University in 2003, 2005, 2007, 2008, and 2011. She received the Bowon Award for Best Research Activity in 2007. She also was awarded the Excellence in Research Award from Korean Society of Gene Therapy (2011, 2012, and 2014), Korean Government Ministry award from Ministry of Science (2013), LG Yonam Foundation (2016), and International Society of Cancer Gene Therapy (2016). As a testament to her boundless pursuit for excellence and scientific advancements, she is a current member of the National Academy of Engineering of Korea. Many of her students from her has gone on to impactful academic and industry careers.
  • Min Liang, Ph.D.

    • Affiliation
    • ▪ Professor, School of Life Science, Shanghai University, Shanghai, China
    • E-mail : liangmin@shu.edu.cn
    • Biography
    • Min Liang , Ph.D.
      Focus on novel oncolytic virus, gene therapy and monoclonal antibody drug research and development. Achieved Ph.D. degree in Fudan University(major in Oncology), Master’s degree in the Institute of Virology(major in Immunology), CAPM, Bachelor’s degree in Wuhan University(major in Biochemistry). As the CSO and Vice President of Sunway Biotech from 1999-2009, Dr.Min Liang lead to develop the Oncorine(H101) oncolytic adenovirus product, which has been launched to Chinese market in 2006. Oncorine is the first approved oncolytic virus product in the world. As the CSO and Executive Vice President of TOTBiopharm Co., Ltd. From 2009-2019, Dr. Min Liang lead to develop a series of monoclonal antibody drugs, antibody-drug conjugates from preclinical to phase III clinical trials. Inventor of a series patents for oncolytic viruses and cancer vaccine. Member of ASGCT(American Society of Gene and Cell Therapy), member of International Committee of ASGCT.
  • Takafumi Nakamura, Ph.D.

    • Affiliation
    • ▪ Associate Professor, Division of Molecular Medicine, Department of Biomedical Science, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
    • E-mail : taka@tottori-u.ac.jp
    • Biography
    • Takafumi Nakamura is serving as Associate Professor in the Division of Molecular Medicine, Department of Biomedical Science, Graduate School of Medical Sciences, Tottori University, Japan. His research interests include 1) oncolytic virotherapy, 2) cancer gene therapy, 3) vaccine against cancer and infectious diseases using viral vectors, 4) gene delivery using viral vectors, 5) targeted molecular therapy, 6) viral entry and fusion for infection, and 6) tumor biology. He has published 55 articles including major academic journals such as Nature Biotechnology, Cancer Research, Clinical Cancer Research, Molecular Therapy, Molecular Therapy Oncolytics, Human Gene Therapy, and Journal of Virology and has registered over 15 patents. Recently, he has been focusing on translating his next-generation oncolytic vaccinia virus pipelines into clinic.
  • Byung Geon (B.G.) Rhee, Ph.D.

    • Affiliation
    • ▪ Chairman, CARM (Council for Advanced Regenerative Medicine) Korea
      ▪ CEO, SCM Lifescience, Seoul, Korea
    • E-mail : bgrhee@scmlifescience.com
    • Biography
    • Dr. B.G. Rhee brings 32 years of experience in R&D and management in bioindustry. He is currently Chairman of CARM (Council for Advanced Regenerative Medicine) and CEO of SCM Lifescience in Korea. SCM Lifescience is developing next generation stem cell therapy products for immune related diseases.
      Prior to his current position, Dr. Rhee was Chairman of Korea BIO (Biotechnology Industry Organization), Vice Chairman of CKD Pharm, President of Green Cross Corp in Korea and CEO of Expression Genetics which is developing non-viral gene therapy products in the US.
      He is Chairman of Korea Support Committee or IVI (International Vaccine Institute), Fellow of National Academy of Engineering Korea and Board member of KISTEP (Korea Institute of Science & Technology Evaluation and Planning) in Korea and also serves as International Advisor for Bio-Economy Committee in Malaysia and for Bioengineering Institute at Rice University, US.
      Dr. Rhee received BS and MS in Chemical Engineering at Seoul National University and holds Ph.D. in Chemical/Biomedical Engineering at Rice University and postdoctoral position at University of Wisconsin-Madison.
  • Sae Won Kim, Ph.D.

    • Affiliation
    • ▪ Senior scientist, Head of immune cell therapy team, SL BIGEN Inc., Seongnam, Korea
    • E-mail : swkim@slbigen.com
    • Biography
    • Sae Won Kim obtained his BS degree in chemical and biomolecular engineering from Johns Hopkins University; and PhD in life sciences from POSTECH (Pohang University of Science and Technology, Korea). He joined a cell and gene therapy company called SL BIGEN, Inc. in 2014 and has been working as a senior scientist and the head of immune cell therapy team. He has 10+ years experience in genetic engineering of stem cell as well as immune cell therapeutics and currently developing CAR(chimeric antigen receptor-modified)-NK therapeutics using his proprietary NK cell line platform.
  • Xiaosong Zhong, M.D., Ph.D.

    • Affiliation
    • ▪ Beijing Shijitan Hospital, Capital Medical University, China
    • E-mail : 15313000323@163.com
    • Biography
    • Dr.Zhong received M.D and M.S degree in Microbiology and Immunology from Jiaotong University, School of Medicine and Master of Biostatistics from Maryland of University, School of Medicine USA . Formerly a senior fellow (tenure) at the U.S. Department of Defense's Center for disease surveillance, a visiting fellow at the FDA (food and Drug Administration). Since 1999 as a visiting scholar to the National Cancer Institute,NIH , has been working in the field of cancer immunotherapy for more than 20 years. Extensive experience in gene therapy and adoptive cell therapy (CAR-T and TCR-T) and he was the earliest inventor of the third generation of CAR-T. He finished his post-doctoral training at Dr.Rosenberg Steven’s laboratory of National Cancer Institute, NIH and Dr.Sadelain Michel’s laboratory at Memorial Sloan-Kettering Cancer Center. He was the tenure senior investigator in the Army force Surveillance Health Center, Department of Defense USA and also was principal investigator at Food and Drug Administrative (FDA). Dr.Zhong is only Chinese who worked at the gene and cell therapy pioneer,Dr.Sadelain Michel’s laboratory of Sloan Kettering Cancer Centerand the pioneer of adoptive cell therapy for caner, Dr.Steven Rosenberg’s laboratory of National Cancer Institute, NIH,USA as a researcher and senior researcher engaged in research and development of CAR-T and TCR-T.During working in Dr.Sadelain Michel’s laboratory, Dr. Zhong conducted the pre-clinical study the first generation and third generation CAR-T (for prostate cancer) as well second CAR-T (CD19 positive CAR-T for lymphoma and leukemia) clinical study (the first successful cure for acute lymphoblastic leukemia in the world) and was the earliest invention of the third generation of CAR-T (Molecular Therapy and The Journal of Immunology). During the period of working , the second generation of CAR-T technology was introduced by Dr.Zhong who also attended the preliminary clinical study for hematologic malignancies and solid tumors in Dr.Rosenberg Steven’s laboratory, (the first successful cure of advanced lymphoma in the world) and Dr.Zhong proposed for the first time and the development of Tscm for the treatment of cancer (Nature Medicine, PubMed in single quoted 300 times), which has been recognized as the next generation of CAR-T (TCR-T) for treatment of cancer and the development of new vaccine direction. Dr.Zhong has been invited to participate in international reports, Medicine (Science, Nature, Nature) is recognized as the next generation of cancer cell therapy and the development of new vaccines in the direction specified .As the first author Dr.Zhong published more than 40 peer review papers, such as Nature Medicine, Molecular Therapy (Nature), Cancer Research, Oncogene, the Journal of Immunology and he is member of the International Association of gene and cell therapy association, the American Association for cancer research and the American Society of clinical oncology.
  • Tomoki Todo, M.D., Ph.D.

    • Affiliation
    • ▪ Professor, Division of Innovative Cancer Therapy and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    • E-mail : toudou-nsu@umin.ac.jp
    • Biography
    • Dr. Todo received his M.D. from the University of Tokyo in 1985 and his Ph.D. in Medical Science from the University of Tokyo in 1994. Following his clinical training in neurosurgery, he served as Staff Neurosurgeon at the International Medical Center of Japan from 1989 through 1995. Dr. Todo received a Board Certification from Japan Neurosurgical Society in 1993.
      Dr. Todo had his training in brain tumor research at Department of Neuropathology of the University of Tokyo and at Department of Neurosurgery of the University of Erlangen-Nürnberg (Erlangen, Germany). In 1995, Dr. Todo joined the Department of Neurosurgery at Georgetown University Medical Center (Washington, DC), and served as Research Assistant Professor from 1998, where he focused his research on oncolytic virus therapy using herpes simplex virus type 1 (HSV-1). From 2000, Dr. Todo served as Assistant Professor of Neurosurgery at Massachusetts General Hospital and Harvard Medical School (Boston, MA). In 2003, he returned to Japan as Assistant Professor of Neurosurgery at the University of Tokyo. From 2008, Dr. Todo served as Professor and Vice Director of Translational Research Center at the University of Tokyo Hospital. He has assumed his current position since July 2011.
      Dr. Todo is one of the pioneers in the field of clinical development of oncolytic HSV-1. Dr. Todo’s accomplishments include the discovery of the induction of systemic antitumor immunity by oncolytic HSV-1. Dr. Todo developed a triple-mutated, third-generation oncolytic HSV-1 (G47∆) that currently awaits New Drug Application in Japan. His research further includes development of new-generation, “armed” oncolytic HSV-1 and their use in a variety of cancer.
      Dr. Todo serves as the Chairman of Board of Directors of Japan Society of Gene & Cell Therapy (JSGCT) since 2018. He was the President of the 25th Annual Meeting of JSGCT (2019). Dr. Todo is an Editorial Board member of journals “Neuro-Oncology”, “Cancer Science” and “Molecular Therapy Oncolytics”.
  • Wenlin Huang, Ph.D. (Sun Yat-Sen Cancer Center)

    • Affiliation
    • ▪ Professor, Sun Yat-Sen University, China
    • E-mail : drhuangwenlin@163.com
    • Biography
    • Dr. Wenlin Huang, a molecular virologist and oncologist. He pursued his career and research at Princeton University in New Jersey (1988 – 1996), Advanced Viral Research Institute in New York (1996–2001), and Sun Yat-Sen University Cancer Center in Guangzhou, China (2001–present). Currently, his research mainly focuses on development of anti-angiogenesis drug with both gene and chemical compound targeting to the specific domain in cancer. He is also an expert in the State Council special funding program, evaluation expert of China Food and Drug Administration (CFDA), professor of Sun Yat-Sen University Cancer experimental research department, vice president of China Medicinal Biotech Association, member of Scientific Committee for State Key Laboratory of Oncology in South China, consultant member of 973 giant grant , and chief editor of national graduate textbook Molecular Virology. Editorial board for Oncology, Cancer Biology, Cancer, Thoracic Cancer etc. At present, he has applied for 34 innovation patents in China, the United States and internationally. Also, he has published over 100 peer reviewed science papers in cutting edge journals, for example Nature Medicine, JCI, Hepatology, Gastroenterology, PNAS, Cancer Research, Biomaterial, Clinical Cancer Research, Journal of Virology, Gene Therapy, and Human Gene Therapy. With his outstanding research for innovation in developing new drugs, he has received quite a amount of fund support from 863 grant, National Innovation Fund for SMEs, Key Science and Technology Projects of Guangdong Province, and Guangzhou Municiple. Moreover, he has been the recipient of the WIPO-SIPO Award for Chinese Outstanding Patented Invention Award, Guangdong Science and Technology Progress Award in 2012, Ministry of Science Education Award, Chun-Hui Cup Competition Excellence Award. In cooperation with the Cancer Center of Sun Yat-Sen Univeristy, one of Dr. Huang’s patent, E10A, a recombinant human endostatin adenovirus injection has been developed for cancer drug, which is currently in completion of phase III clinical trial, thus far this targeted cancer gene therapy has achieved excellent results and registered in America FDA new medicine testing department (www.clinicaltrial.org). Dr. Huang has also completed pre-clinical studies for a recombinant human IFN-γ adenovirus (E10B) and a tyrosine kinase receptor inhibitor (E10C), and applied for phase I clinical trial approval. With the above three new anti-cancer drug R and D from pile up facilitation, it will enhance medical treatment toward cancer and benefit the cancer patients.
  • Hideki Kasuya, MD, Ph.D, FACS.

    • Affiliation
    • ▪ Professor, Cancer Immmune Therapy Research Center, Graduate School of Medicine, Nagoya university, Japan
      ▪ Associate Dean, Graduate School of Medicine, Nagoya university, Japan
    • E-mail : Kasuya@med.nagoya-u.ac.jp
    • Biography
    • Prof. Hideki Kasuya is a Medical Doctor, and PhD (Medical Science) obtained from Nagoya University Graduate School of Medicine. He is holing FACS (Faculty of American College of Surgery), and a councilor of Japanese Society of Gene and Cell Therapy. He spent a time in Mass General Hospital (Dept. of Surgery) as a senior research fellow. Currently Dr. Hideki Kasuya is a Professor and Chairman of Cancer Immune Therapy in Nagoya University Graduate School of Medicine in Japan. His Research theme is Oncolytic herpes virus, C-REV (formerly HF10) and also many sort of new generation Oncolytic herpes virus with therapeutic gene. He has done the first clinical trial using Oncolytic virus HF10 in the world. It was the first clinical trial using Oncolytic virus in Japan. He has been involved in C-REV most recent clinical trial in Japan as a leader of strategy and safety evaluation committee.
  • Ryuichi Morishita, MD, Ph.D.

    • Affiliation
    • ▪ Professor, Professor of Department of Clinical Gene Therapy, Osaka University
      ▪ Founder & Medical Advisor, AnGes Inc.
    • E-mail : morishit@cgt.med.osaka-u.ac.jp
    • Biography
    • Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After following postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003 to present.
      Professor Morishita received over 20 awards from various academic societies including Harry Goldbratt Award in Council of High Blood Pressure, American Heart Association, Award in Japanese of Japan Medical Society, Sato Award in 27th annual meeting of the Japanese Circulation Society and Invitrogen-Nature-Biotechnology Award.
      Professor Morishita is currently on the editorial board of over 30 scientific journals including Open Medicine Journal (Editor-in-Chief), Gene Therapy, ATVB, Circulation and Hypertension. He has published over 400 original articles and review papers, primarily on gene therapy and molecular biology in cardiovascular disease. In addition, Professor Morishita is a Board Member of numerous medical organizations, including Japanese Society of Gene Therapy, Japan Society of Vascular Medicine, Japanese Society of Anti-aging and others.
      He is currently member of Committee for Regulation Reform (Advisor Committee of Shinzo Abe Prime Minister of Japan), and Strategic Advisor of Headquarter for HealthCare Strategy (Chief is Shizo Abe, Prime Minister of Japan). He is also Special Advisor of Osaka Prefecture and Osaka City. He also worked as a member of Intellectual Property Committee of Koizumi & Abe Cabinet. His professional activities & appointments include Committee for Industry-Academia Relationship, Ministry of Education, Science and Culture of Japan, Vice Chairman, Bio-Venture Association Originated from Universities, and others.
  • Masatoshi Tagawa, MD & Ph.D.

    • Affiliation
    • ▪ Professor, Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
      ▪ Clinical Physician, Funabashi Orthopaedic Hospital, Funabashi, Japan
      ▪ Visiting Scientist, Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan
    • E-mail : mtagawa@chiba-cc.jp; mtagawa@fff.or.jp
    • Biography
    • Dr. Masatoshi Tagawa graduated with MD from School of Medicine, Chiba University (Chiba, Japan) and completed the graduated course in Chiba University (awarded PhD) in 1984. He spent a few years in Stanford University (CA, USA) as a postdoctoral fellow and became an assistant professor at Chiba University. He then moved to Chiba Cancer Center Research Institute as a Head in Division of Cell Therapy and Pathology, and became a professor of Graduate School of Medicine at Chiba University. He is now a professor and a visiting scientist at Chiba Universtity and Chiba Cancer Center, respectively, and also works as a clinical physician. He is a council member of the Japan Society of Gene and Cell Therapy and Asian Pacific Consortium of Gene and Cell Therapy , and also serves as an editor of several international medical journals. His primary research field is molecular biology and oncology, and he is currently working on mesothelioma at preclinical and clinical research levels.
  • Paola Grandi, Ph.D.

    • Affiliation
    • ▪ Co-Founder of Oncorus, Joins Cold Genesys as CSO
    • E-mail : paola.grandi@coldgenesys.com
    • Biography
    • Dr. Grandi received a bachelor degree in biology from University of Ferrara in 1996 and her master’s degree in genetics in 1997. She earned a PhD in biochemistry from the University of Ferrara in 2001. Dr. Grandi received a fellowship for U.S. study from University of Ferrara and was a post-doctoral fellow from 2001-2005 in the Molecular Neurogenetics Department at the Massachusetts General Hospital where she studied the effect of the extracellular matrix on vector spreading and replication in a collaborative effort between Dr. Breakfield and Dr. Jain’s labs. In 2005 Dr. Grandi joined the Department of Neurological Surgery as an Assistant Professor at the University of Pittsburgh. In 2017 she accepted the position as a Senior Director of Immunology and Virology at Oncorus, an early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. The core technology was based on Dr. Grandi’s work at the University of Pittsburgh. In 2018 she became CSO at CG Oncology, a late stage biotech company focused on the development of Adenoviral-based vector for treatment of bladder cancer.
  • Keisuke Nimura, Ph.D.

    • Affiliation
    • ▪ Associate Professor, Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan
    • E-mail : nimura@gts.med.osaka-u.ac.jp
    • Biography
    • Keisuke Nimura is serving as an Associate Professor in the Department of Genome Biology Division of Gene Therapy Science at Osaka University Graduate School of Medicine. His research interests focus on elucidating the mechanisms through which dysregulation of gene expression causes diseases. He has investigated the mechanism through which defects in epigenetic regulation or RNA metabolism leads to diseases such as congenital disorders and cancer. His research goal is not limited to elucidating the fundamental biological mechanisms of gene expression in diseases; He also intends to investigate therapeutic strategies for diseases such as cancer.
      Regulation of gene expression is a complex process, and it remains unclear as to how defects in the regulation of gene expression causes diseases. His previous studies have demonstrated the molecular mechanisms through which defects in regulation of gene expression causes diseases, including that of Wolf-Hirschhorn syndrome candidate 1 (Whsc1). Whsc1, a histone H3 lysine 36 trimethyltransferase, plays a critical role in development through transcriptional regulation in conjunction with the homeoprotein Nkx2-5 [Nimura et al. Nature]; it also acts as the transcription factor regulating alternative polyadenylation, which is critical for heart development [Nimura et al. eLife]. He has also demonstrated a dynamic change in chromatin architecture during B cell activation as a model for the transition from a dormant to an active cell cycle state [Nimura (co-first) et al. Molecular Cell]. More recently, He is seeking to understand how cancer cells alter gene expression and splicing to promote tumor malignancy. He has recently found that increased expression of the splicing factor SF3B2 modulates the splicing pattern and determines a splicing variant expression, leading to an aggressive phenotype of prostate cancer. [Nimura (co-first) et al. Cancer Research].
  • Sangsu Bae, Ph.D.

    • Affiliation
    • ▪ Assistant Professor, Department of Chemistry, College of Natural Sciences, Hanyang University, Seoul, Korea
    • E-mail : sangsubae@hanyang.ac.kr
    • Biography
    • Sangsu Bae is serving as an Assistant Professor in Department of Chemistry at Hanyang University, Korea. His research interests include genome editing, RNA editing, bioinformatics, gene therapy, cell imaging, and plant transformation. He has published 48 articles in leading academic journals such as Nature Biotechnology, Cell Stem Cell, Nature Methods, Nature Communications, Molecular Therapy, Oncogene, and Bioinformatics and has registered over 11 patents. Recently, Dr. Bae has been focusing on developing novel genome editing tools using CRISPR-Cas system and applying gene editing tools for gene therapy. He was selected for National R&D Excellence Achievement Top 100 (2018) and received Minister's Commendation, Ministry of Science and ICT (2018). Representative publications are listed as follows.
  • Xin Tan, Ph.D.

    • Affiliation
    • ▪ Research assistant professor, IVF Center, Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
    • E-mail : tanx27@mail.sysu.edu.cn; jessietansysu@163.com
    • Biography
    • Tan Xin is serving as a research assistant professor in Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China. Her research interests mainly focus on the Molecular mechanism of colorectal cancer metastasis. She has identified crucial genes that play critical roles in cancer metastasis and provide new insights into mechanisms of cancer tumorigenesis. She intends to investigated an effective strategy for the future development of anti-tumor therapy.
  • Shuangshuang Lu, Ph.D.

    • Affiliation
    • ▪ Assistant Professor, National Centre for International Research Centre in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, Academy of Medical Sciences, Zhengzhou University, Zhengzhou China
    • E-mail : lushuangshuang@zzu.edu.cn
    • Biography
    • Shuangshuang Lu is serving as an assistant professor at the Academy of Medical Science, Zhengzhou University, China. Her research interests include immunotherapy for pancreatic cancer, lung cancer, esophageal squamous cell carcinoma, and tumor biology. She has published 13 articles in academic journals such as Clinical Cancer Research and Molecular and Cellular Biology. She has presided a project supported by the National Natural Science Foundation of China for youth and participated in two Major Research Plan of the National Natural Science Foundations of China as a major participant. She is the peer reviewer of SCI journals, such as Oncotargets and Therapy and Cancer Management and Research.
  • Xiawei Wei, Ph.D.

    • Affiliation
    • ▪ Director and Professor, Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
    • E-mail : xiaweiwei@scu.edu.cn; paula_8@163.com
    • Biography
    • Xiawei Wei is serving as a director and Full Professor in the Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy in Sichuan University. She also serves as the committee members of Cancer Gene & Cell Therapy Committee and Nanoagents & Synthetic Formulations Committee in American Society of Gene and Cell Therapy. Her major research interests include targeted cancer gene therapy and immunogene therapy by nanocarriers and viral vectors as well as small molecule targeted cancer therapy. She has published 80 articles in leading academic journals such as Cell Research, Nano letters, Hepatolgy etc. She is serving as a Editorial Board Member for several well-recognized international journals include Particle and Fibre Toxicology (Impact Factor: 6.5), Chemico-Biological Interactions, Acta Pharmaceutica Sinica B, Chinese Chemical Letters, Journal of Biomedical Nanotechnology, Nanoscience and Nanotechnology Letters. Dr. Wei is also serving as the Director of the Youth Committee of Asia-Pacific Consortium Gene and Cell Therapy (APCGCT) for four year term (2018-2022) and the Deputy Director of Committee of Regenerative Medicine in China Anti-aging Promoting Association.
  • Sa-Won Lee, Ph.D. (Samyangbiopharm)

    • Affiliation
    • ▪ Team Manager, Pharmaceuticals R&D Team, Samyang Discovery Center, Samyang Biopharmaceuticals Corporation, Seoul, Korea
    • E-mail : sawon.lee@samyang.com
    • Biography
    • Dr. Sa-Won Lee has served as a Team Manager of the Pharmaceuticals R&D Team at Samyang Biopharmaceuticals Corporation, Korea since 2016. His research interests include polymer-based nanomedicine, targeted drug delivery and incrementally modified drugs in the area of cancer. He has led over 27 research projects, of which nine have been approved by KFDA including a polymeric micellar anticancer agent (Nanoxel® M). He has published in areas of pharmaceutical science and drug delivery and has filed or registered over 40 patents. Recently, his research focuses on the development of incrementally modified drugs for the treatment of cancer.
  • A-Rum Yoon, Ph.D.

    • Affiliation
    • ▪ Research Professor, Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea
    • E-mail : ayoon@hanyang.ac.kr
    • Biography
    • Dr. A-Rum Yoon is currently a Research Professor of Bioengineering at Hanyang University, Seoul, Korea. She has received obtained MS (2004) and Ph. D. (2011) degree in Biomedical Science from Yonsei University, Seoul, Korea. From 2008 to 2009, Dr. Yoon has been trained as a guest researcher at the National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba, Japan, during her Ph. D. course. She has completed a postdoctoral fellowship in School of Public Health at Johns Hopkin University, Baltimore, MD, USA (2012-2014). Then, she moved back to Seoul, Korea where he work as a research professor at Hanyang University (2014-). Her research focuses on the development of oncolytic adenovirus, which selectively kills cancer cells, as the baseline platform for the development of various smart adenovirus vector systems. In this regards, her research interests include cancer gene therapy, immunotherapy, combination of viral vectors and non-viral vectors, nanomedicine, and tumor biology.
  • Robert M. Frederickson, Ph.D.

    • Affiliation
    • ▪ Executive Editor, the Molecular Therapy family of journals, official journals of the American Society of Gene & Cell Therapy, published by Cell Press
    • E-mail : editor@molther.org
    • Biography
    • Robert M Frederickson is Executive Editor of the Molecular Therapy family of journals. Robert was appointed Editor of Molecular Therapy in Sept of 2002 and has overseen the growth of the journal group to include three additional titles, Molecular Therapy – Nucleic Acids (2012), Molecular Therapy – Methods & Clinical Development (2014) and Molecular Therapy – Oncolytics (2014). The MT family journals are now the top four journals serving the international gene and cell therapy communities based on Impact Factor and collectively publish a commanding fraction of top-notch research in these areas. Robert received an M.Sc. in Biomedical Physics from the University of Toronto in 1987 and a Ph.D. in Biochemistry and Molecular Biology from McGill University in 1994. Following post-docs at the University of Ottawa and University of Washington, Robert joined Nature Publishing Group as a locum editor at Nature magazine and then as Research Editor at Nature Biotechnology and Senior Editor at Nature Medicine before joining Molecular Therapy in 2002.